Última actualización 15 de agosto de 2026
Key finding
Systolic blood pressure decreased by -10.7 ± 9.6 mmHg (p < 0.001).
This study compared the efficacy and safety of azelnidipine and trichlormethiazide in treating hypertension in type 2 diabetic patients. Both medications showed similar changes in HbA1c levels, but azelnidipine demonstrated greater reductions in blood pressure.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the efficacy and safety of azelnidipine and trichlormethiazide in treating hypertension in type 2 diabetic patients. Both medications showed similar changes in HbA1c levels, but azelnidipine demonstrated greater reductions in blood pressure.
Effective management of hypertension in type 2 diabetic patients is crucial to prevent complications such as cardiovascular disease. This study highlights the potential of azelnidipine as a more effective option for lowering blood pressure compared to trichlormethiazide, which may help clinicians make informed treatment decisions for their patients.
The study did not assess long-term outcomes beyond the trial period. Sample size may limit the generalizability of the findings. Potential confounding factors were not fully controlled.
Published in
Publication details and source links for this paper.
Masahiro T, Akinobu N, Yoshinobu K, et al. Efficacy and Safety of Azelnidipine vs. Trichlormethiazide in Type 2 Diabetic Patients with Hypertension. PLOS ONE. 2015;10(5):e0125519. doi:10.1371/journal.pone.0125519
Azelnidipine reduced systolic blood pressure by -10.7 mmHg (p < 0.001).
Azelnidipine reduced diastolic blood pressure by -6.6 mmHg (p < 0.001).
Dizziness was reported in 11.7% of patients taking azelnidipine.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Azelnidipine, Trichlormethiazide and Diastolic blood pressure, Dizziness incidence, HbA1c, and 2 more.
This study contributes evidence to
Primary intervention
Azelnidipine
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
10
Evidence pairs
391
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Core evidence
The primary outcomes reported in this study.
Azelnidipine → Diastolic blood pressure
Azelnidipine → Diastolic blood pressure
Azelnidipine → Incidence of edema during follow-up
Azelnidipine → Incidence of edema during follow-up
Trichlormethiazide → Diastolic blood pressure
Trichlormethiazide → Diastolic blood pressure
Trichlormethiazide → Incidence of edema during follow-up
Trichlormethiazide → Incidence of edema during follow-up
Trichlormethiazide → Systolic blood pressure
Trichlormethiazide → Systolic blood pressure
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Azelnidipine and Blood Pressure, Azelnidipine and Dizziness incidence.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on Azelnidipine
Contributes to Azelnidipine evidence base.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
All studies measuring Dizziness incidence
Measures Dizziness incidence as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Azelnidipine appears to improve Diastolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Azelnidipine appears to improve Systolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Trichlormethiazide appears to improve Diastolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Trichlormethiazide appears to improve Systolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
